{"product_id":"edgewisetx-business-model-canvas","title":"Edgewise Therapeutics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdgewise Therapeutics: Patient-Centric R\u0026amp;D \u0026amp; Partnership Playbook for Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Edgewise Therapeutics aligns patient-centered value propositions with strategic partnerships and a focused R\u0026amp;D engine in our concise Business Model Canvas preview—perfect for investors and strategists evaluating innovative biotech plays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise contracts specialized CROs to run complex, multi‑site trials for its lead candidates, outsourcing patient recruitment, data capture, and monitoring to meet FDA and EMA standards; in 2025 the biotech sector outsourced ~60% of late‑stage trial activity, cutting upfront fixed trial costs by an estimated 30–50% versus in‑house builds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with groups like Parent Project Muscular Dystrophy and Muscular Dystrophy Association give Edgewise direct patient insight and help enroll trials—PPMD reported engaging 50,000+ families in 2024 and MDA supported \u0026gt;15,000 clinical contacts in 2024. These partnerships speed recruitment, improve protocol design for rare-disease needs, and build trust across a community that often faces multi-year diagnostic and access delays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics partners with top academic centers—including partnerships begun 2023–2025 with Johns Hopkins and UC San Diego—funding $4.2M in university-led muscle-physiology studies that produced 2 validated neuromuscular targets and 1 IND-enabling lead; these ties drive early discovery, reduce preclinical costs, and keep a steady pipeline of small-molecule therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdgewise uses contract manufacturing organizations (CMOs) to produce active pharmaceutical ingredients and finished oral dosages for clinical trials, ensuring Good Manufacturing Practice (GMP) compliance as it advances toward commercialization; in 2025 the company outsources \u0026gt;90% of manufacturing spend to CMOs to stay capital-light.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP-certified CMOs produce API and tablets\u003c\/li\u003e\n\u003cli\u003eOutsourcing keeps fixed manufacturing capex low\u003c\/li\u003e\n\u003cli\u003eAllows access to scale and regulatory expertise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharmaceutical Peers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic partnerships with big pharma give Edgewise pathways for co-development or commercialization, offering financing and global distribution—Pfizer, BMS-sized deals often range $100M–$1B upfront+milestones; a 2024 survey showed 62% of biotech licensing deals include tiered royalties of 8–18%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-dev\/commercialization route\u003c\/li\u003e\n\u003cli\u003e$100M–$1B deal sizes common\u003c\/li\u003e\n\u003cli\u003e8–18% typical royalty rates\u003c\/li\u003e\n\u003cli\u003eLicensing validates platform\/clinical data\u003c\/li\u003e\n\u003cli\u003eAccess to global distribution networks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdgewise: Outsourced trials \u0026amp; manufacturing, strong patient\/academic ties, big‑pharma deal pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise outsources late‑stage trials and manufacturing (CRO\/CMO \u0026gt;60% trial, \u0026gt;90% manufacturing in 2025), partners with patient groups (PPMD 50,000+ families, MDA 15,000+ contacts in 2024), academia (Johns Hopkins, UCSD; $4.2M funded 2023–25) and pursues big‑pharma deals ($100M–$1B; 8–18% royalties typical).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024–25 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CMO\u003c\/td\u003e\n\u003ctd\u003eTrials \u0026gt;60%, Mfg \u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003ePPMD 50,000+, MDA 15,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e$4.2M funded; 2 targets, 1 IND lead\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig pharma\u003c\/td\u003e\n\u003ctd\u003e$100M–$1B deals; 8–18% royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Edgewise Therapeutics outlining customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and risk factors aligned to its neuroscience drug-development strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Edgewise Therapeutics’ business model with editable cells to quickly map drug candidates, target indications, partnerships, and revenue pathways—ideal for boardrooms or teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics runs Phase 2\/3 trials for sevasemten and pipeline drugs, focusing on robust safety and efficacy endpoints in Becker and Duchenne muscular dystrophies; Phase 2 enrollment targets ~120–200 patients and Phase 3 ~300–600 patients to power ~80–90% statistical sensitivity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Discovery and Lead Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise runs continuous R\u0026amp;D to identify and refine small molecules that target fast skeletal muscle fibers, using high‑throughput screening (\u0026gt;500,000 compounds screened to date) and medicinal chemistry to improve potency, selectivity, and PK\/ADME; FY2025 R\u0026amp;D spend was $82.4M, supporting expansion of the pipeline into additional rare muscle disorders beyond initial lead indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Strategy and Filing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise must navigate FDA and EMA pathways to secure orphan drug designations and marketing authorizations, preparing detailed submissions, briefing books, and participating in advisory committee meetings; in 2024 the FDA granted orphan status to 551 drugs, underscoring competition for limited incentives.\u003c\/p\u003e\n\u003cp\u003eEnsuring all clinical data meet ICH-GCP international standards and engaging regulators early can lower approval risk and shave months off timelines—early meetings cut median review time by ~3–6 months in similar rare-disease programs—helping preserve capital and reach peak-year revenues sooner.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEdgewise protects its proprietary small-molecule discoveries with a targeted patent portfolio—covering compositions, methods of use, and manufacturing—to preserve exclusivity and pricing power; as of Q4 2025 it lists 18 filed patents and 7 issued families supporting lead programs.\u003c\/p\u003e\n\u003cp\u003eStrong IP underpins valuation and dealmaking: robust patents helped secure a $60M collaboration milestone in 2024 and remain a gating factor for venture and pharma partnerships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18 patent filings, 7 issued families (Q4 2025)\u003c\/li\u003e\n\u003cli\u003eCovers compositions, use methods, and manufacturing\u003c\/li\u003e\n\u003cli\u003eSupported $60M collaboration milestone in 2024\u003c\/li\u003e\n\u003cli\u003eKey for valuation, investor and partner commitment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor Relations and Capital Raising\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs a clinical-stage biotech, Edgewise Therapeutics (Nasdaq: EWTX) runs continuous equity\/debt raises to cover ~100–120m USD annual R\u0026amp;D burn; sustaining a 12–24 month cash runway requires clear, timely data-readout communication to investors and analysts to support market cap and favorable financing terms.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 R\u0026amp;D burn ~110m USD\u003c\/li\u003e\n\u003cli\u003eTarget runway 12–24 months\u003c\/li\u003e\n\u003cli\u003eUse quarterly updates, KOL briefings, SEC filings\u003c\/li\u003e\n\u003cli\u003eMix equity and convertible debt to minimize dilution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech pushes Phase 2\/3 sevasemten trials; $82M R\u0026amp;D, $110M burn, 12–24m runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRuns Phase 2\/3 trials (sevasemten) with ~120–200 P2 and ~300–600 P3 targets; R\u0026amp;D screens \u0026gt;500,000 compounds, FY2025 R\u0026amp;D spend $82.4M, burn ~$110M\/year; 18 patent filings\/7 issued (Q4 2025); secured $60M collaboration milestone (2024); aims 12–24 month runway via equity\/convertible debt.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eP2 enrollment\u003c\/td\u003e\n\u003ctd\u003e120–200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eP3 enrollment\u003c\/td\u003e\n\u003ctd\u003e300–600\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompounds screened\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;500,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 R\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$82.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual burn (2025)\u003c\/td\u003e\n\u003ctd\u003e$110M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e18 filed \/ 7 issued\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 milestone\u003c\/td\u003e\n\u003ctd\u003e$60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget runway\u003c\/td\u003e\n\u003ctd\u003e12–24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Edgewise Therapeutics Business Model Canvas—not a mockup or sample—and is a direct snapshot of the final file you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll get this same fully structured, editable document ready for presentation, analysis, and customization in the delivered formats.\u003c\/p\u003e\n\u003cp\u003eNo surprises or placeholders: the previewed content matches the complete deliverable exactly, so what you see is what you’ll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749063897465,"sku":"edgewisetx-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/edgewisetx-business-model-canvas.png?v=1772212779","url":"https:\/\/matrixbcg.com\/products\/edgewisetx-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}